Lupus & antiphospholipid syndrome
SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus
Authors' conclusion
SLE disease burden differs with the organ system(s) involved.
Study context
- Population
- Patients with SLE with baseline organ system involvement in four phase III belimumab trials (BLISS-52, BLISS-76, BLISS-SC, EMBRACE)4 phase III trials pooled
- Comparison
- SELENA-SLEDAI organ system responders vs non-responders; and, among responders, belimumab vs placebo
- Outcome
- Changes in health-related quality of life (HRQoL) (SF-36v2) and fatigue (FACIT-Fatigue)
- Follow-up
- Over 52 weeks
Methodological detailsanalysis of variance, published group-level minimal important difference (MID)
- Analysis of variance
- Published group-level MID
Pooled result
As reported in the abstract
SF-36v2 and FACIT-Fatigue changes by organ system response and treatment · 52 weeks
- Musculoskeletal and mucocutaneous responders had greater SF-36v2 improvements than non-responders across most domains, but differences largely <MID
- Most organ system responders had improved FACIT-Fatigue vs non-responders; cardiovascular and respiratory responders ≥MID
- Musculoskeletal and renal responders on belimumab had greater improvements in several SF-36v2 domains than responders on placebo (>MID)
- FACIT-Fatigue improved >MID for renal responders on belimumab
- Post hoc analyses
Original publication
SF-36v2 and FACIT-Fatigue quality of life improvements with organ-specific SELENA-SLEDAI response and belimumab treatment in patients with systemic lupus erythematosus. Lupus Sci Med. Published 8 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →